The Incidence of Thyroid Cancer Among Breast Cancer Survivors
Jennifer H. Kuo, MD, director, Thyroid Biopsy Program, Columbia University, discusses a study looking at the incidence of thyroid cancer among breast cancer survivors.
An Open-Label Extension of SELECT
Lori J. Wirth, MD, discusses an open-label extension of the phase III SELECT trial, which looked at lenvatinib versus placebo for differentiated thyroid cancer.
PARP-1 Has Role in Estrogen-Related Transcription
Poly (ADP-ribose) polymerase-1 (PARP-1) is a multifunctional, chromatin-regulating protein. PARP inhibitors are currently undergoing clinical trials as potential targeted therapies for the treatment of breast, uterine, colorectal, and ovarian cancer.
Enzalutamide Synergizes With Trastuzumab and Everolimus to Inhibit Breast Cancer Growth
The oral androgen receptor inhibitor, enzalutamide, blocks several steps in the androgen receptor signaling pathway and prevents the entry of androgen receptor into the cell nucleus.
AR-V7 in Prostate Cancer Cells Introduces Potential Therapeutic Target for CRPC
A recent study showed that the androgen receptor (AR) splice variant AR-V7 activated full-length AR through an alternative biosynthesis pathway and increased citrate utilization through altered metabolic activities, which may partially explain its resistance to conventional androgen deprivation therapy (ADT).
The Relationship Between Thyroid-Stimulating Hormone Levels and Outcomes From SELECT
Steven I. Sherman, MD, discusses the relationship between thyroid-stimulating hormone levels and outcomes from the phase III SELECT trial.
Approval of Lenvatinib for Advanced Thyroid Cancer: Clinical Implications
On February 13, 2015, the FDA approved lenvatinib for treatment of locally recurrent or metastatic differentiated thyroid cancer that is refractory to radioactive iodine therapy.
Thyroid Hormone Receptor and Runx2 Expression in Thyroid Cancer Cells
Frances Carr, PhD, professor, Department of Pharmacology, The University of Vermont, discusses the relationship between the thyroid hormone receptor and Runx2 expression in thyroid cancer cells.
Exposure to Agent Orange Associated With Increased Prevalence of Thyroid Cancer in Veterans
According to a recent descriptive analysis of the VA Corporate Data Warehouse, veterans who reported Agent Orange exposure had higher rates of thyroid cancer compared to the overall national VA health care patient population.
Geospatial and Temporal Analysis Show Increased Thyroid Cancer Incidence in Rural Population
The incidence of thyroid cancer, which is now the most rapidly increasing endocrine malignancy, has been increasing at a rate of 3% to 5% per year, resulting in a near doubling in the past 30 years.
Thyroiditis in Melanoma Patient Treated With Ipilimumab and Pembrolizumab
In an analysis of adverse events following treatment of patients with advanced melanoma with ipilimumab and nivolumab, combination therapy was associated with a 22% incidence of either thyroiditis or hypothyroidism and a 9% incidence of hypophysitis.
Augmenting Pre-Operative Risk of Recurrence Stratification in DTC
R. Michael Tuttle, MD, discusses a study that looked at augmenting pre-operative risk of recurrence stratification in differentiated thyroid carcinoma.
Cabozantinib Linked to Weight Loss in Patients With Advanced Thyroid Cancer
Tyrosine-kinase inhibitors (TKIs) are a mainstay of therapy for patients with advanced thyroid cancer, more than doubling progression-free survival.
Patients With History of Breast Cancer Have Increased Incidence of Thyroid Cancer
Patients with a history of breast cancer have a higher risk of developing thyroid cancer than do the general population, particularly if they receive adjuvant radiation therapy.
2 Commerce Drive Cranbury, NJ 08512